Riik: Euroopa Liit
keel: inglise
Allikas: EMA (European Medicines Agency)
A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)
GlaxoSmithKline Biologicals S.A.
J07BB02
prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Vaccines
Influenza, Human; Immunization; Disease Outbreaks
Active immunisation against H5N1 subtype of influenza-A virus.This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with H5N1 subtype strains.Prepandrix should be used in accordance with official guidance.
Revision: 13
Withdrawn
2008-05-14
30 B. PACKAGE LEAFLET 31 PACKAGE LEAFLET: INFORMATION FOR THE USER PREPANDRIX SUSPENSION AND EMULSION FOR EMULSION FOR INJECTION Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU RECEIVE THIS VACCINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - This vaccine has been prescribed for you only. Do not pass it on to others. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Prepandrix is and what it is used for 2. What you need to know before you receive Prepandrix 3. How Prepandrix is given 4. Possible side effects 5. How to store Prepandrix 6. Contents of the pack and other information 1. WHAT PREPANDRIX IS AND WHAT IT IS USED FOR WHAT PREPANDRIX IS AND WHAT IT IS USED FOR Prepandrix is a vaccine for use in adults from 18 years old. It is intended to be given before or during the next influenza (flu) pandemic to prevent flu caused by the H5N1 type of the virus. Pandemic flu is a type of influenza that happens at intervals that vary from less than 10 years to many decades. It spreads rapidly around the world. The signs of pandemic flu are similar to those of ordinary flu but may be more serious. HOW PREPANDRIX WORKS When a person is given the vaccine, the body’s natural defence system (immune system) produces its own protection (antibodies) against the disease. None of the ingredients in the vaccine can cause flu. As with all vaccines, Prepandrix may not fully protect all persons who are vaccinated. 2. WHAT YOU NEED TO KNOW BEFORE YOU RECEIVE PREPANDRIX PREPANDRIX SHOULD NOT BE GIVEN: • if you have previously had a sudden life-threatening allergic reaction to any ingredient of this vaccine (listed in section 6) or to anything else that may be present in very small amounts such as: egg and chicken protein, o Lugege kogu dokumenti
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Prepandrix suspension and emulsion for emulsion for injection. Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After mixing, 1 dose (0.5 ml) contains: Split influenza virus inactivated, containing antigen * equivalent to: _ _ A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2) 3.75 micrograms ** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 milligrams), DL- α -tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams) The suspension and emulsion vials once mixed form a multidose container. See section 6.5 for the number of doses per vial. Excipient with known effect The vaccines contains 5 micrograms thiomersal (see section 4.4). For the full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Suspension and emulsion for emulsion for injection. The suspension is a colourless light opalescent liquid. The emulsion is a whitish to yellowish homogeneous milky liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Active immunisation against H5N1 subtype of Influenza A virus. This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with H5N1 subtype strains (see section 5.1). Prepandrix should be used in accordance with official guidance. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults from the age of 18 years: One dose of 0.5 ml at an elected date. A second dose of 0.5 ml should be given after an interval of at least three weeks and up to twelve months after the first dose for maximum efficacy. 3 _Special population: _ Based on very limited data, adults aged >80 years may require a double dose of Prepandrix on an elected date and again after an interval of at least three weeks in order to achieve an immune response (see section 5.1). A complete vaccination course with Prepandrix consists of t Lugege kogu dokumenti